Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
143 hedge funds and large institutions have $571M invested in Array Biopharma Inc in 2013 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 42 increasing their positions, 50 reducing their positions, and 17 closing their positions.
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
7% more funds holding
Funds holding: 134 → 143 (+9)
12% less capital invested
Capital invested by funds: $651M → $571M (-$79.8M)
16% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 50
83% less call options, than puts
Call options by funds: $771K | Put options by funds: $4.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.5M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$13.7M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$4.31M |
| 4 |
DM
Deerfield Management
New York
|
+$3.54M |
| 5 |
PA
Pinnacle Associates
New York
|
+$3.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$11.8M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
-$9.85M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$8.39M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$3.73M |
| 5 |
PA
Perceptive Advisors
New York
|
-$3.56M |
ARRY Hedge Fund Activity: Q4 2013 in Review
143 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2013, worth a combined $571M — down 12% from $651M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ARRY positions and 17 closed out — a net gain of 10 holders — while 42 added to existing stakes and 50 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $43.5M. The largest seller was BVF Inc, cutting an estimated $11.8M.
- 143 institutional investors held Array Biopharma Inc (ARRY) as of Q4 2013, up from 134 in Q3 2013.
- Funds reported $571M of Array Biopharma Inc stock for Q4 2013, down 12% quarter-over-quarter.
- 27 funds opened new Array Biopharma Inc positions in Q4 2013 and 17 closed out, a net change of +10 holders.
- The largest Array Biopharma Inc buyer in Q4 2013 was Fidelity Investments, an estimated $43.5M added.
- The largest Array Biopharma Inc seller in Q4 2013 was BVF Inc, an estimated $11.8M sold.
Based on aggregated 13F filings for Q4 2013.